Tufts Clinical and Translational Science Institute

塔夫茨临床与转化科学研究所

基本信息

  • 批准号:
    10622002
  • 负责人:
  • 金额:
    $ 1139.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-05-01 至 2030-04-30
  • 项目状态:
    未结题

项目摘要

TUFTS CTSI OVERALL PROJECT SUMMARY Over its 14 years, Tufts Clinical and Translational Science Institute (CTSI) has brought together partners and collaborators and has grown programs and activities to catalyze clinical and translational research (CTR) and to advance innovation in clinical and translational science (CTS). We focus on what we are best suited to do, based on our skills, resources, partners, and opportunities. Thereby, we provide outstanding services, resources, education, and mentorship, and conduct innovative research contributing to the field of CTS, locally and nationally. With this application, retaining our important structural features of integration across all of Tufts University, of having purposefully-selected partners, and adhering to our foundational principles, we are pleased to further grow our offerings and ambitions leveraging our long-standing partners’ contributions and assets and by adding the special assets of new partners. With growth, our foundational principles have not changed. We actively support the full spectrum of translational research, we practice “broadly-engaged team science,” and we are active collaborators, embracing our role as “the extrovert CTSA.” We believe that only by having systems and processes to continually assess and improve methods and operational principles will we achieve CTR/CTS excellence. We practice inclusive communications and work to advance health equity. And we insist that wherever work is on the T.5-T4 continuum, CTR must have a clear line of sight to potential ultimate impact on health. In addition to these foundational principles, in all we do, we reflexively look for opportunities to contribute novel research methods. Development, demonstration, and dissemination of new methods and approaches are hallmarks of our work, regardless of domain. Also, we manifest our belief that rigorous role-specific inclusive education and training are fundamental to excellence and advancing CTR/CTS. In service of these principles, our aims are: Overall AIM 1: Harness the collective impact of Tufts CTSI to advance CTS and improve public health through responsive Hub leadership, an inclusive and collaborative culture, and continuous improvement of programs and research. Overall AIM 2: Provide outstanding education, training, and mentoring, tailored to different roles and disciplines, to develop an expert and diverse CTS workforce, and share these resources nationally. Overall AIM 3: Cultivate broadly-engaged team science, with active inclusion of all stakeholders, to promote relevant and impactful translation for diverse populations and to promote health equity. Overall AIM 4: Create the environment, resources, and services to stimulate and support the full spectrum of CTS by leveraging the diverse expertise and assets of Tufts CTSI partners. Overall AIM 5: Foster translation by developing, demonstrating, and disseminating innovations that address significant translational roadblocks and provide generalizable translational insights and solutions.
TUFTS CTSI 总体项目摘要 14 年来,塔夫茨临床与转化科学研究所 (CTSI) 汇聚了合作伙伴 和合作者,并制定了促进临床和转化研究 (CTR) 的计划和活动 并推动临床和转化科学(CTS)的创新。我们专注于我们最适合的事情 根据我们的技能、资源、合作伙伴和机会去做。因此,我们提供卓越的服务, 资源、教育和指导,并开展为当地 CTS 领域做出贡献的创新研究 和全国范围内。通过此应用程序,保留了我们在所有塔夫茨大学中集成的重要结构特征 大学,拥有精心挑选的合作伙伴,并坚持我们的基本原则,我们是 很高兴利用我们长期合作伙伴的贡献和 资产并通过添加新合作伙伴的特殊资产。 随着增长,我们的基本原则没有改变。我们积极支持全方位 转化研究,我们实践“广泛参与的团队科学”,我们是积极的合作者, 接受我们作为“外向 CTSA”的角色。我们相信,只有通过系统和流程 不断评估和改进方法和运营原则,我们才能实现卓越的 CTR/CTS。我们 实行包容性沟通并努力促进健康公平。我们坚持认为无论工作在哪里 在 T.5-T4 连续体中,CTR 必须对健康的潜在最终影响有清晰的认识。此外 这些基本原则,在我们所做的一切中,我们本能地寻找贡献新颖研究的机会 方法。新方法和途径的开发、示范和传播是 我们的工作,无论领域如何。此外,我们表达了我们的信念:严格的针对特定角色的包容性教育和 培训是卓越和提高 CTR/CTS 的基础。 为了服务于这些原则,我们的目标是: 总体目标 1:利用塔夫茨 CTSI 的集体影响力 通过积极响应的中心领导力、包容性和协作性,推进 CTS 并改善公共卫生 文化,以及项目和研究的持续改进。总体目标 2:提供卓越的 针对不同角色和学科量身定制的教育、培训和指导,培养专家和多元化的人才 CTS 员工队伍,并在全国范围内共享这些资源。总体目标 3:培养广泛参与的团队 科学,所有利益相关者的积极参与,促进不同领域的相关和有影响力的翻译 人口并促进健康公平。总体目标 4:创造环境、资源和服务 利用塔夫茨 CTSI 的多元化专业知识和资产,刺激和支持全方位的 CTS 合作伙伴。总体目标 5:通过开发、展示和传播创新来促进翻译 解决重大的转化障碍并提供通用的转化见解和解决方案。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Harry P. Selker其他文献

Is primary angioplasty for some as good as primary angioplasty for all?
  • DOI:
    10.1046/j.1525-1497.2002.11232.x
  • 发表时间:
    2002-12-01
  • 期刊:
  • 影响因子:
    4.200
  • 作者:
    David M. Kent;Christopher H. Schmid;Joseph Lau;Harry P. Selker
  • 通讯作者:
    Harry P. Selker
Academic General Internal Medicine: A Mission for the Future
  • DOI:
    10.1007/s11606-013-2334-3
  • 发表时间:
    2013-01-16
  • 期刊:
  • 影响因子:
    4.200
  • 作者:
    Katrina Armstrong;Nancy L. Keating;Michael Landry;Bradley H. Crotty;Russell S. Phillips;Harry P. Selker
  • 通讯作者:
    Harry P. Selker
Physician electrocardiogram reading in the emergency department—Accuracy and effect on triage decisions
  • DOI:
    10.1007/bf02599153
  • 发表时间:
    1992-07-01
  • 期刊:
  • 影响因子:
    4.200
  • 作者:
    Robert L. Jayes;Greg C. Larsen;Joni R. Beshansky;Ralph B. D’Agostino;Harry P. Selker
  • 通讯作者:
    Harry P. Selker
Extending the electrocardiogram's role to address patient safety and quality improvement practices
  • DOI:
    10.1016/j.jelectrocard.2005.06.046
  • 发表时间:
    2005-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    Manlik Kwong;Denise Hartnett Daudelin;Harry P. Selker;Joni R. Beshansky
  • 通讯作者:
    Joni R. Beshansky
Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials
  • DOI:
    10.1016/j.ahj.2017.02.028
  • 发表时间:
    2017-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    Harry P. Selker;James E. Udelson;Robin Ruthazer;Ralph B. D'Agostino;Melissa Nichols;Ori Ben-Yehuda;Ingo Eitel;Christopher B. Granger;Paul Jenkins;Akiko Maehara;Manesh R. Patel;E. Magnus Ohman;Holger Thiele;Gregg W. Stone
  • 通讯作者:
    Gregg W. Stone

Harry P. Selker的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Harry P. Selker', 18)}}的其他基金

Tufts Clinical and Translational Science Institute (Clinical Trial Design Labs Supplement)
塔夫茨临床和转化科学研究所(临床试验设计实验室补充材料)
  • 批准号:
    10844980
  • 财政年份:
    2023
  • 资助金额:
    $ 1139.42万
  • 项目类别:
Tufts Clinical and Translational Science Institute
塔夫茨临床与转化科学研究所
  • 批准号:
    9816143
  • 财政年份:
    2018
  • 资助金额:
    $ 1139.42万
  • 项目类别:
Tufts Clinical and Translational Science Institute
塔夫茨临床与转化科学研究所
  • 批准号:
    10412102
  • 财政年份:
    2018
  • 资助金额:
    $ 1139.42万
  • 项目类别:
Tufts Clinical and Translational Science Institute
塔夫茨临床与转化科学研究所
  • 批准号:
    10159334
  • 财政年份:
    2018
  • 资助金额:
    $ 1139.42万
  • 项目类别:
Tufts Clinical and Translational Science Institute (Pilot Supplement)
塔夫茨临床与转化科学研究所(试点增刊)
  • 批准号:
    10260036
  • 财政年份:
    2018
  • 资助金额:
    $ 1139.42万
  • 项目类别:
Tufts Clinical and Translational Science Institute (N3C Supplement)
塔夫茨临床与转化科学研究所(N3C 增刊)
  • 批准号:
    10172199
  • 财政年份:
    2018
  • 资助金额:
    $ 1139.42万
  • 项目类别:
Tufts Clinical and Translational Research Institute
塔夫茨临床与转化研究所
  • 批准号:
    8743320
  • 财政年份:
    2013
  • 资助金额:
    $ 1139.42万
  • 项目类别:
Tufts Clinical and Translational Research Institute
塔夫茨临床与转化研究所
  • 批准号:
    9278321
  • 财政年份:
    2013
  • 资助金额:
    $ 1139.42万
  • 项目类别:
Tufts Clinical and Translational Research Institute
塔夫茨临床与转化研究所
  • 批准号:
    8720917
  • 财政年份:
    2013
  • 资助金额:
    $ 1139.42万
  • 项目类别:
Tufts Clinical and Translational Research Institute
塔夫茨临床与转化研究所
  • 批准号:
    8720923
  • 财政年份:
    2013
  • 资助金额:
    $ 1139.42万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 1139.42万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1139.42万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 1139.42万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1139.42万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 1139.42万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 1139.42万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1139.42万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 1139.42万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 1139.42万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 1139.42万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了